News of Note—Merck Big Data; AbbVie JAK1 win; Bayer, Vanderbilt deal

Deals for European pharmas as AbbVie gets RA data win

> Merck KGaA is joining forces with non-profit Project Data Sphere as the pair eye working on a new, global cancer Big Data alliance. Release

> AbbVie has posted positive top-line results from the late-stage test of upadacitinib, its investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis. The candidate hit its primary and secondary endpoints, but two deaths hit the company's sharesJefferies however say: "The deaths were considered by investigators to have no reasonable possibility of being related to upadacitinib at the time of initial reporting.". Statement

> German pharma Bayer and the Vanderbilt University Medical Center have penned a five-year R&D alliance aimed at finding new therapies against kidney diseases. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

 

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.